Pamela Salman
- Obstetrics and Gynecology top 2%
- Endometrial and Cervical Cancer Treatments 13
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 17
- CAR-T cell therapy research 3
- Reproductive Medicine top 5%
-
- Colorectal and Anal Carcinomas 5
-
- Cervical Cancer and HPV Research 4
-
- Lung Cancer Treatments and Mutations 3
- Advanced Breast Cancer Therapies 2
-
- Melanoma and MAPK Pathways 3
Pamela Salman
22 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 60
- Obstetrics and Gynecology 382
- Oncology 646
- Reproductive Medicine 139
- Immunology 177
- Cancer Research 109
Countries citing papers authored by Pamela Salman
This map shows the geographic impact of Pamela Salman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Salman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Salman more than expected).
Fields of papers citing papers by Pamela Salman
This network shows the impact of papers produced by Pamela Salman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Salman. The network helps show where Pamela Salman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Pamela Salman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 9 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 3 | |
| 5 | First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826breakdown → | 2023 | 100 |
| 6 | 2023 | 2 | |
| 7 | 2023 | 37 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 21 | |
| 10 | 2023 | 68 | |
| 11 | 2022 | 10 | |
| 12 | 2022 | 9 | |
| 13 | 2022 | 1 | |
| 14 | 2022 | 10 | |
| 15 | 2021 | 4 | |
| 16 | Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancerbreakdown → | 2021 | 581 |
| 17 | 2020 | 3 | |
| 18 | 2019 | 36 | |
| 19 | 2017 | 106 | |
| 20 | [MALT lymphoma of the bladder: report of a case]. | 1998 | 9 |
About Pamela Salman
Pamela Salman is a scholar working on Obstetrics and Gynecology, Oncology and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (17 papers), Endometrial and Cervical Cancer Treatments (13 papers), Colorectal and Anal Carcinomas (5 papers), Cervical Cancer and HPV Research (4 papers), CAR-T cell therapy research (3 papers), Lung Cancer Treatments and Mutations (3 papers), Melanoma and MAPK Pathways (3 papers) and Advanced Breast Cancer Therapies (2 papers). The work is most often cited by research in Obstetrics and Gynecology (382 citations), Oncology (646 citations) and Reproductive Medicine (139 citations). Pamela Salman has collaborated with scholars based in United States, Chile and Italy. Frequent co-authors include Vanessa Samouëlian, Ronnie Shapira‐Frommer, Mivael Olivera, Vincent Castonguay, Coraline Dubot, Kan Li, Krishnansu S. Tewari, Kosei Hasegawa, Bradley J. Monk and Domenica Lorusso. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, JAMA Oncology, Frontiers in Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.